Cotellic

RSS

cobimetinib

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Cotellic. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Cotellic.

For practical information about using Cotellic, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 14/06/2022

Authorisation details

Product details
Name
Cotellic
Agency product number
EMEA/H/C/003960
Active substance
cobimetinib hemifumarate
International non-proprietary name (INN) or common name
cobimetinib
Therapeutic area (MeSH)
Melanoma
Anatomical therapeutic chemical (ATC) code
L01XE38
Publication details
Marketing-authorisation holder
Roche Registration GmbH
Revision
12
Date of issue of marketing authorisation valid throughout the European Union
20/11/2015
Contact address

Emil-Barell-Strasse 1
79639 Grenzach-Wyhlen
Germany

Product information

19/05/2022 Cotellic - EMEA/H/C/003960 - II/0025

This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Antineoplastic agents

Therapeutic indication

Cotellic is indicated for use in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

Assessment history

Related content

How useful was this page?

Add your rating
Average
1 rating